Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfobromophthalein is a synthetic dye and small molecule used primarily as a diagnostic agent to assess liver function in humans. It acts as a substrate for organic anion transporting polypeptide (OATP) and is transported into hepatocytes, where it undergoes conjugation with glutathione before being excreted into bile via multidrug resistance-associated protein 2 (MRP2). Its hepatic uptake and biliary excretion are the basis for its use in the bromsulphthalein test of liver function. Sulfobromophthalein can also inhibit aldo-keto reductase AKR1C20 and has been shown to inhibit the biliary secretion of glutathione by directly inhibiting the GSH transport process. The compound has been used since at least 1925 for hepatic diagnostics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfobromophthalein.